Metabolic Disorders and Anesthesia


Purpose of Review

Metabolic disorders encompass a group of inherited inborn errors of metabolism that are uncommonly encountered but can pose challenges when encountered during the perioperative period. Hence, it is paramount that anesthesiologists are experienced and familiar with management of these conditions.

Recent Findings

Hundreds of inborn errors of metabolism have already been identified, yet new metabolic disorders continue to be discovered with advancements in genomic science.


In our general review, we define the more common metabolic disorders encountered in perioperative medicine and discuss the perioperative anesthetic considerations and challenges associated with each disorder. The following disorders are covered in our review: disorders of carbohydrate metabolism, disorders of amino acid metabolism, disorders of branched-chain amino acid metabolism, organic acidemias, mitochondrial disorders, lysosomal storage disorders, metal metabolism disorders, and urea cycle disorders.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    •• Kliegman R, Stanton B, Schor N, St. Geme J III, Behrman R. Nelson Textbook of Pediatrics. 19th ed: Elsevier Health Sciences; 2011. Published in 2011 this is a textbook review of common metabolic disorders

  2. 2.

    Coelho AI, Rubio-Gozalbo ME, Vicente JB, Rivera I. Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis. 2017;40:325–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Karadag N, Zenciroglu A, Eminoglu FT, Dilli D, Karagol BS, Kundak A, et al. Literature review and outcome of classic galactosemia diagnosed in the neonatal period. Clin Lab. 2013;59:1139–46.

    PubMed  Google Scholar 

  4. 4.

    Dhillon A, Steadman RH. In: Fleisher LA, editor. Liver diseases, anesthesia and uncommon diseases. 6th ed. Philadelphia: Elsevier Saunders; 2012. p. 162–214.

    Google Scholar 

  5. 5.

    Choudhury A, Das S, Kiran U. Anaesthetic management of a newborn with galactosaemia for congenital heart surgery. Indian Journal of Anaesthesia. 2009;53:219–22.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Stuart G, Ahmad N. Perioperative care of children with inherited metabolic disorders. Continuing Education in Anaesthesia Critical Care & Pain. 2011;11:62–8.

    Google Scholar 

  7. 7.

    Hammond S, Krol A, Hampson-Evans D. Normoglycaemia in type 1b glycogen storage disease with difficult venous access. Anaesthesia. 2009;64:1150.

    CAS  PubMed  Google Scholar 

  8. 8.

    Shenkman Z, Golub Y, Meretyk S, Shir Y, Landau D, Landau EH. Anaesthetic management of a patient with glycogen storage disease type 1b. Can J Anaesth. 1996;43:467–70.

    CAS  PubMed  Google Scholar 

  9. 9.

    Bevan JC. Anaesthesia in Von Gierke’s disease. Current approach to management. Anaesthesia. 1980;35:699–702.

    CAS  PubMed  Google Scholar 

  10. 10.

    Yu X, Huang Y, Du J. Bispectral index may not reflect the depth of anaesthesia in a patient with glycogen storage disease type I. Br J Anaesth. 2009;103:616.

    CAS  PubMed  Google Scholar 

  11. 11.

    Wang LY, Ross AK, Li JS, Dearmey SM, Mackey JF, Worden M, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth. 2007;17:738–48.

    PubMed  Google Scholar 

  12. 12.

    Ing RJ, Cook DR, Bengur RA, Williams EA, Eck J, Dear Gde L, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth. 2004;14:514–9.

    PubMed  Google Scholar 

  13. 13.

    Kim WS, Cho AR, Hong JM, Kim ES, Park SC, Yoon JY, et al. Combined general and epidural anesthesia for major abdominal surgery in a patient with Pompe disease. J Anesth. 2010;24:768–73.

    PubMed  Google Scholar 

  14. 14.

    McFarlane HJ, Soni N. Pompe’s disease and anaesthesia. Anaesthesia. 1986;41:1219–24.

    CAS  PubMed  Google Scholar 

  15. 15.

    Moses SW, Gadoth N, Bashan N, Ben-David E, Slonim A, Wanderman KL. Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand. 1986;75:289–96.

    CAS  PubMed  Google Scholar 

  16. 16.

    Momoi T, Sano H, Yamanaka C, Sasaki H, Mikawa H. Glycogen storage disease type III with muscle involvement: reappraisal of phenotypic variability and prognosis. Am J Med Genet. 1992;42:696–9.

    CAS  PubMed  Google Scholar 

  17. 17.

    Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV. Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol. 1984;53:980–1.

    CAS  PubMed  Google Scholar 

  18. 18.

    Miller CG, Alleyne GA, Brooks SE. Gross cardiac involvement in glycogen storage disease type 3. Br Heart J. 1972;34:862–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Tada H, Kurita T, Ohe T, Shimomura K, Ishihara T, Yamada Y, et al. Glycogen storage disease type III associated with ventricular tachycardia. Am Heart J. 1995;130:911–2.

    CAS  PubMed  Google Scholar 

  20. 20.

    LaBarbera M, Milechman G, Dulbecco F. Premature coronary artery disease in a patient with glycogen storage disease III. J Invasive Cardiol. 2010;22:E156–8.

    PubMed  Google Scholar 

  21. 21.

    Mohart D, Russo P, Tobias JD. Perioperative management of a child with glycogen storage disease type III undergoing cardiopulmonary bypass and repair of an atrial septal defect. Paediatr Anaesth. 2002;12:649–54.

    PubMed  Google Scholar 

  22. 22.

    Bolton SD, Clark VA, Norman JE. Multidisciplinary management of an obstetric patient with glycogen storage disease type 3. Int J Obstet Anesth. 2012;21:86–9.

    CAS  PubMed  Google Scholar 

  23. 23.

    Bollig G. McArdle’s disease (glycogen storage disease type V) and anesthesia--a case report and review of the literature. Paediatr Anaesth. 2013;23:817–23.

    PubMed  Google Scholar 

  24. 24.

    Baum V, O’Flaherty J. Anesthesia for genetic, metabolic, and dysmorphic syndromes of childhood, 2nd ed edition. Philadelphia: Lippincott Williams & Wilkins; 2007.

    Google Scholar 

  25. 25.

    Coleman P. McArdle’s disease. Problems of anaesthetic management for Caesarean section. Anaesthesia. 1984;39:784–7.

    CAS  PubMed  Google Scholar 

  26. 26.

    Bollig G, Mohr S, Raeder J. McArdle’s disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand. 2005;49:1077–83.

    CAS  PubMed  Google Scholar 

  27. 27.

    Luzardo GE, Karlnoski RA, Williams B, Mangar D, Camporesi EM. Anesthetic management of a parturient with hyperhomocysteinemia. Anesth Analg. 2008;106:1833–6.

    PubMed  Google Scholar 

  28. 28.

    Slote MU, Khan KK, Khan AA, Butt MN. Is homocystinuria a real challenge for anesthetist? Are we making a difference? Saudi J Anaesth. 2018;12:172–3.

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351:36–7.

    CAS  PubMed  Google Scholar 

  30. 30.

    Al-Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol. 2000;36:1217–22.

    CAS  PubMed  Google Scholar 

  31. 31.

    Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279–98.

    CAS  PubMed  Google Scholar 

  32. 32.

    Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–64.

    CAS  PubMed  Google Scholar 

  33. 33.

    Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355:517–22.

    CAS  PubMed  Google Scholar 

  34. 34.

    Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf. 2004;3:101–11.

    CAS  PubMed  Google Scholar 

  35. 35.

    Zhang Q, Li S, Li L, Li Q, Ren K, Sun X, et al. Metformin treatment and homocysteine: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8.

  36. 36.

    Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473–501.

    CAS  PubMed  Google Scholar 

  37. 37.

    Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296:2720–6.

    CAS  PubMed  Google Scholar 

  38. 38.

    Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol. 2010;106:517–27.

    PubMed  Google Scholar 

  39. 39.

    Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E. Heart Outcomes Prevention Evaluation I: homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146:761–7.

    PubMed  Google Scholar 

  40. 40.

    den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007;109:139–44.

    Google Scholar 

  41. 41.

    Behman REKR, Jenson HB. Nelson textbook of paediatrics. 16th ed; 2000.

    Google Scholar 

  42. 42.

    Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21:2080–5.

    CAS  PubMed  Google Scholar 

  43. 43.

    Teng YH, Sung CS, Liao WW, Kao SC, Huang YY, Tsou MY, et al. General anesthesia for patient with homocystinuria--a case report. Acta Anaesthesiol Sin. 2002;40:153–6.

    PubMed  Google Scholar 

  44. 44.

    Badner NH, Beattie WS, Freeman D, Spence JD. Nitrous oxide-induced increased homocysteine concentrations are associated with increased postoperative myocardial ischemia in patients undergoing carotid endarterectomy. Anesth Analg. 2000;91:1073–9.

    CAS  PubMed  Google Scholar 

  45. 45.

    Stoelting RKDS. Anaesthesia and coexisting diseases. 4th ed. Philadelphia: Churchill Livingstone; 2002.

    Google Scholar 

  46. 46.

    National Institutes of Health Consensus Development P. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics. 2001;108:972–82.

    Google Scholar 

  47. 47.

    Douglas TD, Jinnah HA, Bernhard D, Singh RH. The effects of sapropterin on urinary monoamine metabolites in phenylketonuria. Mol Genet Metab. 2013;109:243–50.

    CAS  PubMed  Google Scholar 

  48. 48.

    Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103:1169–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Lee P, Smith I, Piesowicz A, Brenton D. Spastic paraparesis after anaesthesia. Lancet. 1999;353:554.

    CAS  PubMed  Google Scholar 

  50. 50.

    Dal D, Celiker V. Anaesthetic management of a strabismus patient with phenylketonuria. Paediatr Anaesth. 2003;13:740–1.

    PubMed  Google Scholar 

  51. 51.

    Rayadurg V, Uttarwar A, Surve R. Is propofol safe in patients with phenylketonuria? J Neurosurg Anesthesiol. 2018;30:85–6.

    PubMed  Google Scholar 

  52. 52.

    Rivera-Cruz B. Mitochondrial diseases and anesthesia: a literature review of current opinions. AANA J. 2013;81:237–43.

    PubMed  Google Scholar 

  53. 53.

    Rech VC, Feksa LR, Dutra-Filho CS, Wyse AT, Wajner M, Wannmacher CM. Inhibition of the mitochondrial respiratory chain by phenylalanine in rat cerebral cortex. Neurochem Res. 2002;27:353–7.

    CAS  PubMed  Google Scholar 

  54. 54.

    Delaney A, Gal Thomas J. Hazards of anesthesia and operation in maple-syrup-urine disease. Anesthesiology. 1976;44:83–6.

    CAS  PubMed  Google Scholar 

  55. 55.

    Kahraman S, Ercan M, Akkus O, Ercelen O, Erdem K, Coskun T. Anaesthetic management in maple syrup urine disease. Anaesthesia. 1996;51:575–8.

    CAS  PubMed  Google Scholar 

  56. 56.

    Griffiths S, Stuart, G., Alp Karahan, M., & Frazier, D.: Anaesthesia recommendations for patients suffering from Maple syrup urine disease. . 2015

    Google Scholar 

  57. 57.

    Hamosh A, Kniffin, C., Krasikov, N., & McKusick, V. : Maple syrup urine disease; MSUD. . 2018

    Google Scholar 

  58. 58.

    Fuentes-Garcia D, Falcon-Arana L. Perioperative management of a patient with maple syrup urine disease. BJA: Br J Anaesth. 2009;102:144–5.

    CAS  PubMed  Google Scholar 

  59. 59.

    Vaidyanathan K, Narayanan MP, Vasudevan DM. Organic acidurias: an updated review. Indian J Clin Biochem. 2011;26:319–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    • Baumgartner MR, Horster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. Guidelines developed using the SIGN methodology by having professionals on MMA/PA across twelve European countries and the USA gather all the existing evidence, score it according to the SIGN evidence level system, and make a series of conclusive statements supported by an associated level of evidence.

    PubMed  PubMed Central  Google Scholar 

  61. 61.

    Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for organic acidemias: methylmalonic acidemia and propionic acidemia. Pediatr Emerg Care. 2017;33:142–6.

    PubMed  Google Scholar 

  62. 62.

    Shaikh N, Hashmi MG, Shah C, Dhansura T. Anaesthetic considerations in a patient with methylmalonyl-coenzyme A mutase deficiency. Indian J Anaesth. 2017;61:1018–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Sharar SR, Haberkern CM, Jack R, Scott CR. Anesthetic management of a child with methylmalonyl-coenzyme A mutase deficiency. Anesth Analg. 1991;73:499–501.

    CAS  PubMed  Google Scholar 

  64. 64.

    Arcas-Bellas JJ, Arevalo-Ludena J, Onate ML, Aranzubia M, Alvarez-Rementeria R, Munoz-Alameda L. General anesthesia in an adult female with propionic acidemia: anesthetic considerations. Minerva Anestesiol. 2013;79:313–5.

    CAS  PubMed  Google Scholar 

  65. 65.

    Harker HE, Emhardt JD, Hainline BE. Propionic acidemia in a four-month-old male: a case study and anesthetic implications. Anesth Analg. 2000;91:309–11.

    CAS  PubMed  Google Scholar 

  66. 66.

    Karagoz AH, Uzumcugil F, Celebi N, Canbay O, Ozgen S. Anesthetic management of a 2-year-old male with propionic acidemia. Paediatr Anaesth. 2006;16:1290–1.

    CAS  PubMed  Google Scholar 

  67. 67.

    Rajakumar A, Kaliamoorthy I, Reddy MS, Rela M. Anaesthetic considerations for liver transplantation in propionic acidemia. Indian J Anaesth. 2016;60:50–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Ryu J, Shin YH, Ko JS, Gwak MS, Kim GS. Intractable metabolic acidosis in a child with propionic acidemia undergoing liver transplantation -a case report. Korean J Anesthesiol. 2013;65:257–61.

    PubMed  PubMed Central  Google Scholar 

  69. 69.

    Baba C, Kasahara M, Kogure Y, Kasuya S, Ito S, Tamura T, et al. Perioperative management of living-donor liver transplantation for methylmalonic acidemia. Paediatr Anaesth. 2016;26:694–702.

    PubMed  Google Scholar 

  70. 70.

    Ktena YP, Ramstad T, Baker EH, Sloan JL, Mannes AJ, Manoli I, et al. Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients. J Inherit Metab Dis. 2015;38:847–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Ruzkova K, Weingarten TN, Larson KJ, Friedhoff RJ, Gavrilov DK, Sprung J. Anesthesia and organic aciduria: is the use of lactated Ringer’s solution absolutely contraindicated? Paediatr Anaesth. 2015;25:807–17.

    PubMed  Google Scholar 

  72. 72.

    Weinberg GL, Laurito CE, Geldner P, Pygon BH, Burton BK. Malignant ventricular dysrhythmias in a patient with isovaleric acidemia receiving general and local anesthesia for suction lipectomy. J Clin Anesth. 1997;9:668–70.

    CAS  PubMed  Google Scholar 

  73. 73.

    Soberon JR, Elliott CE, Bland KS, Weinberg GL. Peripheral nerve block in a patient with propionic acidemia. Reg Anesth Pain Med. 2014;39:560–1.

    PubMed  Google Scholar 

  74. 74.

    DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348:2656–68.

    CAS  PubMed  Google Scholar 

  75. 75.

    •• Hsieh VC, Krane EJ, Morgan PG. Mitochondrial Disease and Anesthesia. J Inborn Errors Metab Screen. 2017;5:2326409817707770. Published in 2017, this is a good review of mitochondrial disease and anesthesia.

    Google Scholar 

  76. 76.

    Muravchick S, Levy RJ. Clinical implications of mitochondrial dysfunction. Anesthesiology. 2006;105:819–37.

    CAS  PubMed  Google Scholar 

  77. 77.

    • Niezgoda J, Morgan PG. Anesthetic considerations in patients with mitochondrial defects. Paediatr Anaesth. 2013;23:785–93. Published in 2013, this review provides detailed anesthetic considerations for patients with mitochondrial disorders.

    PubMed  PubMed Central  Google Scholar 

  78. 78.

    Hanley PJ, Ray J, Brandt U, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol. 2002;544:687–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 2001;357:606–7.

    CAS  PubMed  Google Scholar 

  80. 80.

    Weinberg GL, Palmer JW, VadeBoncouer TR, Zuechner MB, Edelman G, Hoppel CL. Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology. 2000;92:523–8.

    CAS  PubMed  Google Scholar 

  81. 81.

    Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009;11:414–30.

    PubMed  PubMed Central  Google Scholar 

  82. 82.

    Richtsfeld M, Belani KG. Lysosomal storage diseases: past, present, and future. Anesth Analg. 2017;125:716–8.

    PubMed  Google Scholar 

  83. 83.

    Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27.

    PubMed  Google Scholar 

  84. 84.

    Yuasa T, Takenaka T, Higuchi K, Uchiyama N, Horizoe Y, Cyaen H, et al. Fabry disease. J Echocardiogr. 2017;15:151–7.

    PubMed  Google Scholar 

  85. 85.

    Clark BM, Sprung J, Weingarten TN, Warner ME. Anesthesia for patients with mucopolysaccharidoses: comprehensive review of the literature with emphasis on airway management. Bosnian J Basic Med Sci. 18:1–7.

  86. 86.

    Scarpa M, Lourenco CM, Amartino H. Epilepsy in mucopolysaccharidosis disorders. Mol Genet Metab. 2017;122(s):55–61.

    CAS  Google Scholar 

  87. 87.

    Mueller P, Attenhofer Jost CH, Rohrbach M, Valsangiacomo Buechel ER, Seifert B, Balmer C, et al. Cardiac disease in children and young adults with various lysosomal storage diseases: comparison of echocardiographic and ECG changes among clinical groups. Int J Cardiol Heart Vessel. 2013;2:1–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93:528–35.

    PubMed  PubMed Central  Google Scholar 

  89. 89.

    Megens JH, de Wit M, van Hasselt PM, Boelens JJ, van der Werff DB, de Graaff JC. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatr Anaesth. 2014;24:521–7.

    PubMed  Google Scholar 

  90. 90.

    Mattioli C, Gemma M, Baldoli C, Sessa M, Albertin A, Beretta L. Sedation for children with metachromatic leukodystrophy undergoing MRI. Paediatr Anaesth. 2007;17:64–9.

    PubMed  Google Scholar 

  91. 91.

    Santamaria F, Montella S, Mirra V, De Stefano S, Andria G, Parenti G. Respiratory manifestations in patients with inherited metabolic diseases. 2013;22:437–53.

  92. 92.

    Maria Fuller PJM, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview, Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.

    Google Scholar 

  93. 93.

    Gahl WA. Cystinosis, Pediatric Nephrology. Berlin: Springer; 2009.

    Google Scholar 

  94. 94.

    Schneider JA, Schulman JD. Cystinosis and the Fanconi syndrome. In: Andreoli TDHJF, Fanestil DD, Schultz SG, editors. Physiology of Membrane Disorders. Boston: Springer; 1986.

    Google Scholar 

  95. 95.

    Cherqui S, Courtoy PJ. The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nat Rev Nephrol. 2017;13:115–31.

    CAS  PubMed  Google Scholar 

  96. 96.

    Ioscovich A, Elstein Y, Halpern S, Vatashsky E, Grisaru-Granovsky S, Elstein D. Anesthesia for obstetric patients with Gaucher disease: survey and review. Int J Obstet Anesth. 2004;13:244–50.

    CAS  PubMed  Google Scholar 

  97. 97.

    Hernandez-Palazon J. Anaesthetic management in children with metachromatic leukodystrophy. Paediatr Anaesth. 2003;13:733–4.

    PubMed  Google Scholar 

  98. 98.

    Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet. 2008;9:359–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99.

    Campo M, Berliner N. Hemophagocytic lymphohistiocytosis in adults. Hematol Oncol Clin North Am. 2015;29:915–25.

    PubMed  Google Scholar 

  100. 100.

    • Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loreal O. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016. Published in 2018, this is a recent overview of hemochromatosis.

    PubMed  Google Scholar 

  101. 101.

    Ganz T. Iron and infection. Int J Hematol. 2018;107:7–15.

    CAS  PubMed  Google Scholar 

  102. 102.

    Zamboni P, Tognazzo S, Izzo M, Pancaldi F, Scapoli GL, Liboni A, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg. 2005;42:309–14.

    PubMed  Google Scholar 

  103. 103.

    Ozkurt S, Acikalin MF, Temiz G, Akay OM, Soydan M. Renal hemosiderosis and rapidly progressive glomerulonephritis associated with primary hemochromatosis. Ren Fail. 2014;36:814–6.

    CAS  PubMed  Google Scholar 

  104. 104.

    Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. American Association for the Study of Liver D: diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328–43.

    PubMed  PubMed Central  Google Scholar 

  105. 105.

    Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant. 2010;15:269–76.

    PubMed  Google Scholar 

  106. 106.

    Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009;88:219–25.

    PubMed  Google Scholar 

  107. 107.

    Barg A, Elsner A, Hefti D, Hintermann B. Total ankle arthroplasty in patients with hereditary hemochromatosis. Clin Orthop Relat Res. 2011;469:1427–35.

    PubMed  Google Scholar 

  108. 108.

    Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol. 2006;20:257–60.

    PubMed  PubMed Central  Google Scholar 

  109. 109.

    Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, et al. National Hemochromatosis Transplant R: survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129:494–503.

    PubMed  Google Scholar 

  110. 110.

    Gerhard GS, Chokshi R, Still CD, Benotti P, Wood GC, Freedman-Weiss M, et al. The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients. Patient Saf Surg. 2011;5:1.

    PubMed  PubMed Central  Google Scholar 

  111. 111.

    Shander A, Berth U, Betta J, Javidroozi M. Iron overload and toxicity: implications for anesthesiologists. J Clin Anesth. 2012;24:419–25.

    CAS  PubMed  Google Scholar 

  112. 112.

    • Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–13. A comprehensive overview of Wilson’s and other copper disorders from 2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  113. 113.

    Clayton PT. Inherited disorders of transition metal metabolism: an update. J Inherit Metab Dis. 2017;40:519–29.

    CAS  PubMed  Google Scholar 

  114. 114.

    Li K, Lindauer C, Haase R, Rudiger H, Reichmann H, Reuner U, et al. Autonomic dysfunction in Wilson’s disease: a comprehensive evaluation during a 3-year follow up. Front Physiol. 2017;8:778.

    PubMed  PubMed Central  Google Scholar 

  115. 115.

    Kuan P. Cardiac Wilson’s disease. Chest. 1987;91:579–83.

    CAS  PubMed  Google Scholar 

  116. 116.

    Grandis DJ, Nah G, Whitman IR, Vittinghoff E, Dewland TA, Olgin JE, et al. Wilson’s Disease and Cardiac Myopathy. Am J Cardiol. 2017;120:2056–60.

    PubMed  Google Scholar 

  117. 117.

    Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis. 2017;2:101–39.

    PubMed  PubMed Central  Google Scholar 

  118. 118.

    Langley A, Dameron CT. Copper and anesthesia: clinical relevance and management of copper related disorders. Anesthesiol Res Pract. 2013;2013:750901.

    PubMed  PubMed Central  Google Scholar 

  119. 119.

    Kobayashi M. The effects of sevoflurane and isoflurane on hepatic blood flow in man. Masui. 1996;45:281–6.

    CAS  PubMed  Google Scholar 

  120. 120.

    Baykal M, Karapolat S. Anesthetic management of a pediatric patient with wilsons disease. J Clin Med Res. 2010;2:99–101.

    PubMed  PubMed Central  Google Scholar 

  121. 121.

    Foubert-Samier A, Kazadi A, Rouanet M, Vital A, Lagueny A, Tison F, et al. Axonal sensory motor neuropathy in copper-deficient Wilson’s disease. Muscle Nerve. 2009;40:294–6.

    PubMed  Google Scholar 

  122. 122.

    Blair NF, Cremer PD, Tchan MC. Urea cycle disorders: a life-threatening yet treatable cause of metabolic encephalopathy in adults. Pract Neurol. 2015;15:45–8.

    PubMed  Google Scholar 

  123. 123.

    • Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32. Published in 2012, this comprehensive overview of urea cycle disorders incorporates new trends and emerging therapies.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Cindy Yeoh.

Ethics declarations

Conflict of Interest

Cindy B. Yeoh, Howard C. Teng, Jacob C. Jackson, Lee P. Hingula, Takeshi Irie, Aron Legler, Corrine E. Levine, Iris Chu, Casey M. Chai, and Luis E. Tollinche declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Anesthesia

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yeoh, C., Teng, H., Jackson, J. et al. Metabolic Disorders and Anesthesia. Curr Anesthesiol Rep 9, 340–359 (2019).

Download citation


  • Metabolic disorders
  • Carbohydrate metabolism
  • Amino acid metabolism
  • Branched-chain amino acid metabolism
  • Organic acidemias
  • Mitochondrial disorders
  • Lysosomal storage disorders
  • Metal metabolism disorders
  • Urea cycle disorders
  • Anesthesia